Calcipotriol induces the production of CTACK/CCL27, one of the potential suppressive factors in psoriasis inflammation

Karakawa, Masaru; Kishimoto, Megumi; Ohtsuki, Mamitaro; Komine, Mayumi

doi:10.1111/1346-8138.16152

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTACK is a kind of skin-specific chemokines expressed by keratinocytes, which can mediate the migration of lymphocytes into the skin by binding to CCR10 ( 30 ). It had been thoroughly researched in skin diseases including atopic dermatitis (AD) and psoriasis ( 31 , 32 ). Serum CTACK was shown to be higher in AD patients and correlated with disease severity both in children with atopic and non-atopic dermatitis as well as children with asthma and urticaria ( 33 , 34 ).…”

Section: Discussionmentioning

confidence: 99%

Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: A Mendelian randomization

et al. 2023

View full text Add to dashboard Cite

ObjectivesPrevious studies have reported that a few inflammatory cytokines have associations with systemic lupus erythematosus (SLE)—for example, IL-6, IL-17, and macrophage inflammatory protein (MIP). This Mendelian randomization was conducted to further assess the causal correlations between 41 inflammatory cytokines and SLE.MethodsThe two-sample Mendelian randomization utilized genetic variances of SLE from a large publicly available genome-wide association study (GWAS) (7,219 cases and 15,991 controls of European ancestry) and inflammatory cytokines from a GWAS summary containing 8,293 healthy participants. Causalities of exposures and outcomes were explored mainly using inverse variance weighted method. In addition, multiple sensitivity analyses including MR-Egger, weighted median, simple mode, weighted mode, and MR-PRESSO were simultaneously applied to strengthen the final results.ResultsThe results indicated that cutaneous T cell-attracting chemokine (CTACK) and IL-17 may be suggestively associated with the risk of SLE (odds ratio, OR: 1.21, 95%CI: 1.04–1.41, p = 0.015; OR: 1.37, 95%CI: 1.03–1.82, p = 0.029). In addition, cytokines including beta nerve growth factor, basic fibroblast growth factor, IL-4, IL-6, interferon gamma-induced protein 10, monokine induced by interferon-gamma, MIP1b, stromal cell-derived factor-1 alpha, and tumor necrosis factor-alpha are suggested to be the consequences of SLE disease (Beta: 0.035, p = 0.014; Beta: 0.021, p = 0.032; Beta: 0.024, p = 0.013; Beta: 0.019, p = 0.042; Beta: 0.040, p = 0.005; Beta: 0.046, p = 0.001; Beta: 0.021, p = 0.029; Beta: 0.019, p = 0.045; Beta: 0.029, p = 0.048).ConclusionThis study suggested that CTACK and IL-17 are probably the factors correlated with SLE etiology, while a couple of inflammatory cytokines are more likely to be involved in SLE development downstream.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: A Mendelian randomization

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Studies on CTACK and autoimmune diseases are limited. Among them, observational studies have shown that restoration of the CTACK/CCR10 immunoregulatory impairments caused by psoriasis suppresses skin T-cell hyperactivation, thereby reducing the inflammatory response associated with psoriasis ( 28 , 29 ). An in vitro study found that CTACK/CCL27 significantly inhibited the migration of human subchondral mesenchymal progenitor cells in synovial fluid to the site of microfracture defects, thereby adversely affecting the prognosis of RA patients ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Associations of the circulating levels of cytokines with risk of ankylosing spondylitis: a Mendelian randomization study

Ye,

Wang,

Zhong

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundObservational studies have shown that changes in circulating cytokine/growth factor levels occur throughout the initiation and progression of ankylosing spondylitis (AS), yet whether they are etiologic or downstream effects remains unclear. In this study, we performed a summarized-level bidirectional Mendelian randomization (MR) analysis to shed light on the causal relationship between the two.MethodsGenetic instrumental-variables (IVs) associated with circulating cytokine/growth factor levels were derived from a genome-wide association study (GWAS) of 8,293 European individuals, whereas summary data for the AS were obtained from a FinnGen GWAS of 166,144 participants. We used the inverse-variance-weighted (IVW) method as the main analysis for causal inference. Furthermore, several sensitivity analyses (MR-Egger, weighted median, MR-PRESSO and Cochran’s Q test) were utilized to examine the robustness of the results. Finally, reverse MR analysis was performed to assess reverse causality between AS and circulating cytokine/growth factor levels.ResultsAfter Bonferroni correction, circulating levels of Cutaneous T-cell attracting (CTACK) and Monocyte specific chemokine 3 (MCP-3) were positively associated with a higher risk of AS (odds ratio [OR]: 1.224, 95% confidence interval [95% Cl]: 1.022 ~ 1.468, P = 0.028; OR: 1.250, 95% Cl: 1.016 ~ 1.539, P = 0.035). In addition, elevated circulating levels of Basic fibroblast growth factor (FGF-basic), Granulocyte colony-stimulating factor (G-CSF) and MCP-3 was considered a consequence of AS disease (β = 0.023, P = 0.017; β = 0.017, P = 0.025; β = 0.053, P = 0.025). The results of the sensitivity analysis were generally consistent.ConclusionThe present study supplies genetic evidence for the relationship between circulating cytokine levels and AS. Targeted interventions of specific cytokines may help to reduce the risk of AS initiation and progression.

show abstract

Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids

Gisondi,

Gracia-Cazaña,

Kurzen

et al. 2024

JCM

View full text Add to dashboard Cite

The combined treatment with calcipotriol (Cal) and betamethasone dipropionate (BDP) has emerged as the leading anti-psoriatic topical treatment. Fixed-dose Cal/BDP is available in different formulations, including ointment, gel, foam, and cream. This review examines the mechanism of action of Cal/BDP underlying its therapeutic effect and compiles the evidence regarding its efficacy and safety compared to monotherapy with topical corticosteroids. The dual-action of Cal/BDP targets the inflammatory pathways and abnormal keratinocyte proliferation, both of them fundamental mechanisms of psoriasis pathogenesis. A large number of randomized, double-blind studies support Cal/BDP superiority over topical corticosteroids, demonstrating its broad efficacy across several degrees of psoriasis severity and its capability to provide early significant clinical improvements. This increased efficacy is achieved without negative effects on the safety profile, since the incidence of adverse effects reported with Cal/BDP is usually similar to that of BDP and even lower than that of Cal alone. The combination therapy rapid onset of action, coupled with a simplified dosing regimen, has been identified as crucial for improving long-term adherence and patient outcomes. In conclusion, Cal/BDP is confirmed as a versatile, effective, and convenient option for the patient in psoriasis management.

show abstract

Calcipotriol induces the production of CTACK/CCL27, one of the potential suppressive factors in psoriasis inflammation

Cited by 3 publications

References 8 publications

Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: A Mendelian randomization

Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: A Mendelian randomization

Associations of the circulating levels of cytokines with risk of ankylosing spondylitis: a Mendelian randomization study

Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids

Contact Info

Product

Resources

About